Physician profile
Jillian E Miller
NPI 1710485461
$1,408.52
in general payments reported to CMS, 2019-2025
10 companies · $639 in 2025
The $639 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $269 · 2024: $501 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $511.19 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $306.95 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $228.93 | 2023-2025 | Jemperli, Zejula |
| Genmab U.S., INC. | $119.81 | 2023-2025 | Tivdak |
| Astrazeneca Pharmaceuticals LP | $94.92 | 2024-2025 | Lynparza |
| Exact Sciences Corporation | $52.86 | 2025 | The Cologuard Plus Collection Kit |
| Biogen, INC. | $28.84 | 2025 | Zurzuvae |
| Pharmacosmos Therapeutics INC. | $27.82 | 2025 | Monoferric |
| Smith+Nephew, INC. | $20.50 | 2023 | Versajet, Grafix Pl, Oasis |
| Myriad Genetic Laboratories, INC. | $16.70 | 2024 | Mychoice Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.